patients with resectable liver metastases from colorectal cancer
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Histological Diagnosis: Histopathologically confirmed adenocarcinoma of colorectal cancer. 2. Primary Tumor Location and Resection: The primary tumor is located in the colon (cecum, colon, sigmoid rectum) or rectum and has been resected. Appendiceal and anal canal cancers are excluded. 3. Liver Metastases: No distant metastases other than liver metastases, and curative hepatectomy is planned for the first time. Cases involving systemic chemotherapy enabling curative liver resection (conversion therapy) are also eligible. 4. Age: 20 years or older at the time of consent acquisition. 5. Performance Status: ECOG PS of 0 or 1. 6. Informed Consent: Written informed consent for study participation was obtained from the patient.
Exclusion criteria
Exclusion criteria: 1. Active Double Cancer: Active overlapping cancers at the time of hepatectomy. Exceptions include: (a) relapse-free period of more than 5 years, (b) localized cancers cured through local treatment (e.g., basal or squamous cell carcinoma of the skin, superficial bladder cancer, cervical cancer, ductal carcinoma in situ, or mucosal carcinoma), or (c) non-metastatic prostate cancer not requiring systemic treatment. 2. Pregnancy or Breastfeeding: Pregnancy or lactation at the time of the study. 3. Serious Complications: Patients with severe comorbidities that could affect the safety or proper implementation of the study. 4. Viral Infections: Positive for HBs antigen, HCV antibody, or HIV antibody. 5. Medical Inappropriateness: Deemed unsuitable for the study by the attending physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of this study is the interval between the detection of ctDNA positivity and the clinical diagnosis of recurrence. | — |
Countries
Japan
Contacts
Osaka General Medical Center Department of Gastroenterological Surgery